Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial.

MLA

Donate-Correa, Javier, et al. “Pentoxifylline Ameliorates Subclinical Atherosclerosis Progression in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Randomized Pilot Trial.” Cardiovascular Diabetology, vol. 23, no. 1, Aug. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12933-024-02393-x.

APA

Donate-Correa, J., Ferri, C. M., Mora-Fernández, C., Pérez-Delgado, N., González-Luis, A., & Navarro-González, J. F. (2024). Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial. Cardiovascular Diabetology, 23(1), 1–12. https://doi.org/10.1186/s12933-024-02393-x

Chicago

Donate-Correa, Javier, Carla M. Ferri, Carmen Mora-Fernández, Nayra Pérez-Delgado, Ainhoa González-Luis, and Juan F. Navarro-González. 2024. “Pentoxifylline Ameliorates Subclinical Atherosclerosis Progression in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Randomized Pilot Trial.” Cardiovascular Diabetology 23 (1): 1–12. doi:10.1186/s12933-024-02393-x.